A randomized, placebo‐controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin

Ítems similars

• A randomized, placebo‐controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control
  per: Kadowaki, Takashi, et al.
  Publicat: (2021)
• A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control
  per: Gantz, Ira, et al.
  Publicat: (2017)
• A randomized, placebo‐ and sitagliptin‐controlled trial of the safety and efficacy of omarigliptin, a once‐weekly dipeptidyl peptidase‐4 inhibitor, in Japanese patients with type 2 diabetes
  per: Gantz, Ira, et al.
  Publicat: (2017)
• Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetes
  per: Tajima, Naoko, et al.
  Publicat: (2013)
• Efficacy and safety of ipragliflozin as an add‐on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial
  per: Han, Kyung‐Ah, et al.
  Publicat: (2018)